Who we are
Tetra Health is an Australian based company that facilitates safe and responsible access to medicinal cannabis treatment. Our aim is to educate healthcare providers on the prescription of medicinal cannabis and manage treatment outcomes, providing ongoing support and patient monitoring from our nurse specialists.
Our network of partners have managed over 30,000 global patients with a diverse list of indications and comorbidities while collecting quality patient data, and we have leveraged this international experience and intellectual property to become a leading service provider in Australia.
What We Do
Tetra has used this expertise to assist healthcare providers to make evidence-based, data-driven treatment decisions. Tetra currently services a number of healthcare providers and their patients across multiple disease states, offering premium health services, including;
- CPD Accredited Training
- Streamlined Patient Access
- Nurse Specialist Support
- Personalised Treatment Plans
- Patient Monitoring
- Treatment Progress Reports
- Patient Assessment
- Data Management
- 1-800 Support Line
Our experience in Australia to date has demonstrated our ability to acheive better patient outcomes and allowed us to build supportive systems for healthcare providers on the foundation of clinical research, controlled administration and continuous care.
Tetra has built a team of experts on its Senior Management team, Board of Directors and Medical Advisory Board with years of relevant and diverse experience across global medical cannabis and healthcare industries.
Medical Advisory Board
Professor Andrew McLachlan
Professor Andrew McLachlan is the Head of School and Dean of Pharmacy in the Sydney Pharmacy School and a Member of the Order of Australia. He is currently the Program Director of the NHMRC Centre for Research Excellence in Medicines and Ageing. He is the former Professor of Pharmacy (Aged Care) (2006-2018) in the then Faculty of Pharmacy and at Concord Hospital’s Centre for Education and Research on Ageing.
Andrew is a pharmacist, academic and researcher experienced in clinical and experimental pharmacology and research on the quality use of medicines. His research focuses on understanding the variability in response to medicines and how this can be managed to optimise patient care, particularly in special patient populations such as older people, the very young and the critically ill. He is interested in translating clinical pharmacology research and high quality clinical trial evidence into real-world practice.
Dr Mona Singh
- Member of CESPHN Clinical Advisory Committee
- Medical Editor CESPHN
- Medical Officer/Director BUPA
- BUPA (BMVS) Education Committee Member
Professor Stephen Clarke
Professor Stephen Clarke is a medical oncologist, pharmacologist and translational researcher with major clinical and research interests in gastrointestinal and thoracic cancers and pharmacology. He is a medical oncologist at the Northern Cancer Institute and Royal North Shore Hospital, Director of Cancer Services at Northern Sydney Local Health District and Professor of Medicine at the University of Sydney.
Stephen is Head of the NSW committee of the RACP and is Oncology Advisor to the Department of Veterans Affairs as well as a Member of the Repatriation Pharmaceutical Review Committee.
Professor Philip Morris
Professor Philip Morris is qualified in psychiatry and addiction medicine in Australia. He is Executive Director of the Australian and New Zealand Mental Health Association and Medical Director of the Gold Coast Memory Disorders Clinic. He is a Distinguished Fellow and Board Director of the Pacific Rim College of Psychiatry. He is a member of the Repatriation Pharmaceutical Reference Committee, Senior Medical Advisor to the Department of Veterans’ Affairs and an external assessor for the Therapeutic Goods Administration. Dr Morris is Professor at the Faculty of Health Sciences and Medicine, Bond University.
His clinical and research interests include the psychiatric care of older adult patients, medical and surgical patients, neuropsychiatry/psychogeriatric, post-trauma syndromes, clinical drug trials, and co morbid drug and alcohol and psychiatric conditions.
Professor Paul Glare
Professor Paul Glare is the Chair of Pain Medicine in the Northern Clinical School of the University of Sydney and Director of the University’s Pain Management Research Institute (PMRI).
Prior to this appointment, Professor Glare was Chief of the Pain & Palliative Care Service, Memorial Sloan Kettering Cancer Center in New York with an affiliated appointment as Professor of Medicine at Weill Cornell Medical College. Professor Glare is also Head of Discipline, Pain Medicine, in the Faculty of Medicine at the University of Sydney, and is on the Board of PMRI Ltd, a community based foundation supporting the efforts of the PMRI.
Associate Professor Kellie Charles
Associate Professor Kellie Charles is a cancer pharmacologist with a research interest in the interactions between inflammation, the immune system and cancer chemotherapy outcomes. She is the Head of the Cancer Therapeutics Research Laboratory at the University of Sydney and 15 years of clinical and translational research experience.
Dr Samuel Banister
Dr Samuel Banister is a Senior Research Fellow in the School of Chemistry at The University of Sydney. He brings more than 10 years of experience drug discovery and cannabinoid science to the role. Dr Banister has recently returned to Australia after completing postdoctoral training in radiochemistry, positron emission tomography (PET) imaging, and drug development at Stanford University. His research is centred on the use of cannabinoids for the treatment of epilepsy, affective disorders, and pain.